Abstract

In recent years, prostate specific membrane antigen (PSMA) PET has attracted attention in the diagnosis of recurrence and metastasis of prostate cancer. PSMA is a membrane protein which shows increased expression in more than 90% of prostate cancer, and is known to exhibit high expression in many metastatic and recurrent lesions. In Osaka University Hospital, a clinical research using [18F]PSMA-1007 PET has been conducted since September 2019, and more than 150 scans has been performed so far in patients with prostate cancer with various stages.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.